Alcon Diclofenac Label Change Planned Following AE Reports

Alcon has initiated discussions with FDA to develop new class labeling that better addresses adverse events associated with ophthalmic NSAID use, the company announced following its Aug. 20 suspension of distribution of diclofenac sodium ophthalmic solution due to reports of serious corneal adverse events.